Document is current

Article History

Received: 14 November 2022

Revised: 4 April 2023

Accepted: 25 April 2023

First Online: 19 May 2023

Competing interests

: Dr. Nitya Raj: research funding (ITM, Corcept Therapeutics), consulting/advisory boards (Ipsen Pharma, HRA Pharma, Progenics Pharmaceuticals, AAA). Dr. Jennifer Chan: consulting/advisory boards (TerSera, AAA, Curium), honorarium (Ipsen), stock ownership (Merck). Dr. Rahul Aggarwal: research funding (Merck). Dr. Lawrence Fong: research funding (Roche/Genentech, Abbvie, Bavarian Nordic, Bristol Myers Squibb, Dendreon, Janssen, Merck, Partner Therapeutics), advisory boards (Actym, Allector, Astra Zeneca, Atreca, Bioalta, Bolt, Bristol Myer Squibb, Daiichi Sankyo, Immunogenesis, Innovent, Merck, Merck KGA, Nutcracker, RAPT, Scribe, Senti, Soteria, Sutro, Roche/Genentech). Dr. Thomas Hope: research funding (Clovis Oncology, GE Healthcare, Philips, AAA), consulting (Bayer, Curium, ITM, RayzeBio), advisory boards (Blue Earth Diagnostics, Ipsen), stock ownership (RayzeBio). Dr. Claire Mulvey: research funding (Genentech). Dr. Pamela Munster: research funding (Merck). Dr. Kimberly Perez: consulting/scientific advisory boards (Lantheus, Helsinn/QED). Dr. Diane Reidy-Lagunes: research funding (Merck, Ipsen, Novartis). The remaining authors declare no competing interests.

: The study was reviewed by the University of California San Francisco (UCSF), Memorial Sloan Kettering Cancer Center (MSK), and Dana-Farber Cancer Institute (DFCI) Institutional Review Boards and was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines. All patients provided written informed consent before study enrolment.

: Not applicable.